Stay updated on IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Sign up to get notified when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.

Latest updates to the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page's revision label was updated from v3.4.3 to v3.5.0. No substantive study content changes are indicated.SummaryDifference0.0%

- Check14 days agoChange DetectedAdded Hepatocellular carcinoma as a topic. Included a Resources section with a link to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the site.SummaryDifference0.0%

- Check29 days agoNo Change Detected
- Check45 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing v3.4.1, indicating a minor site update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed.SummaryDifference0.0%

- Check66 days agoChange DetectedAdded a 'Show glossary' option and updated metadata with 'Last Update Submitted that Met QC Criteria' and the Revision label to v3.4.0 (replacing v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Enter your email address, and we'll notify you when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.